AJCDRCT
Efficacy and Safety of SSGJ-608 in Moderate-to-Severe Plaque Psoriasis
A Pivotal Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase III Clinical Trial.
ConclusionSSGJ-608 showed rapid and robust clinical response at week 12 and through week 52, and was well tolerated in Chinese patients with moderate-to-severe plaque psoriasis.
Han L, Qin H, … senior author Xu JAmerican Journal of Clinical Dermatology